Servier shared a post on LinkedIn:
“We are pleased to announce the completion of the acquisition of Day One Biopharmaceuticals, further strengthening our rare oncology portfolio and pipeline.
This acquisition reinforces our leadership in glioma and expands our oncology footprint with the addition of a marketed product and a pipeline focused on rare cancers—fully aligned with our Servier 2030 ambition.
It represents a key milestone in our long-term strategy to strengthen our position in rare cancers and continue advancing research for patients with high unmet medical needs.
Learn more about our commitment to oncology.”
More posts about Servier.